1. Home
  2. ARVN vs TECX Comparison

ARVN vs TECX Comparison

Compare ARVN & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.04

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$30.89

Market Cap

549.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARVN
TECX
Founded
2015
2019
Country
United States
United States
Employees
N/A
60
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
658.2M
549.5M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ARVN
TECX
Price
$8.04
$30.89
Analyst Decision
Buy
Strong Buy
Analyst Count
19
5
Target Price
$15.05
$75.20
AVG Volume (30 Days)
680.3K
121.2K
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
58.84
N/A
EPS
N/A
N/A
Revenue
$262,600,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.06
$14.39
52 Week High
$14.22
$35.99

Technical Indicators

Market Signals
Indicator
ARVN
TECX
Relative Strength Index (RSI) 46.65 58.40
Support Level $7.35 $27.31
Resistance Level $10.18 $31.39
Average True Range (ATR) 0.41 1.77
MACD 0.17 0.16
Stochastic Oscillator 70.20 83.62

Price Performance

Historical Comparison
ARVN
TECX

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: